Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its innovative antibody drug conjugate (ADC), SHR-A1921. The study will evaluate the efficacy and safety of SHR-A1921 in combination with aumolertinib or bevacizumab plus chemotherapy for the treatment of patients with advanced solid tumors.
SHR-A1921 is an in-house developed ADC that targets TROP2, a protein overexpressed in various cancers. The drug works by binding to the target antigen on the surface of tumor cells, leading to endocytosis and the subsequent release of small-molecule toxins that kill the cancer cells. This ADC has previously been granted a fast-track designation (FTD) by the US Food and Drug Administration (FDA) and a breakthrough therapy designation (BTD) by the NMPA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.- Flcube.com
